Interferon Patents (Class 930/142)
  • Patent number: 7812126
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: October 12, 2010
    Assignee: Schering Corporation
    Inventors: Christi L. Parham, Kevin W. Moore, Nicholas J. Murgolo, J. Fernando Bazan
  • Patent number: 7446173
    Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: November 4, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
  • Patent number: 7214367
    Abstract: The present invention includes interferon-tau (IFN?) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: May 8, 2007
    Inventors: Jeanne M. Soos, Joel Schiffenbauer, Howard Marcellus Johnson
  • Patent number: 6962978
    Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: November 8, 2005
    Assignee: Biogen, Inc.
    Inventors: Blake Pepinsky, Laura Runkel, Margot Brickelmaier, Adrian Whitty, Paula Hochman
  • Patent number: 6372206
    Abstract: The invention includes interferon-tau (IFN&tgr;) pharmaceutical compositions useful for oral administration to treat autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.
    Type: Grant
    Filed: March 15, 1996
    Date of Patent: April 16, 2002
    Assignee: University of Florida
    Inventors: Jeanne M. Soos, Joel Schiffenbauer, Howard Marcellus Johnson
  • Patent number: 5989839
    Abstract: Disclosed is a method of determining the presence and activity of interferon inhibitors in a test sample, preferably human blood serum. The method includes the steps of culturing cells which express an interferon-inducible antigen in the presence of an interferon and then adding an aliquot of the cultured cells to a test sample and to a control sample. The expression of the interferon-inducible antigen is then measured in both the test sample and in the control sample and these two values compared to determine the presence and activity of interferon inhibitors in the test sample.
    Type: Grant
    Filed: August 19, 1997
    Date of Patent: November 23, 1999
    Assignee: Ghassan I. Shaker
    Inventors: Rajko D. Medenica, David K. Powell
  • Patent number: 5681723
    Abstract: The present invention is drawn to mutant interleukin 6, which has the amino acid arginine in position 176, replacing serine in position 176 with wild-type interleukin 6. The mutant interleukin 6 of the present invention has greater biological activity than the wild-type protein. The present invention is further drawn to methods of making mutant interleukin 6, having arginine at position 176 and methods of using the same.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: October 28, 1997
    Assignee: Instituto di Ricerche di Biologia Molecolare P. Angelett S.P.A.
    Inventors: Gennaro Ciliberto, Rocco Savino
  • Patent number: 5114711
    Abstract: Described is a new class of polypeptide cell modulators characterized by being composed of two covalently linked cell modulators in a linear polypeptide sequence. Such dual function polypeptides have new and particularly useful activities when the component polypeptide cell modulators are interferons, lymphokines or cytotoxins which act through different and specific cell receptors to initiate complementary biological activities.
    Type: Grant
    Filed: July 13, 1989
    Date of Patent: May 19, 1992
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, Keith G. McCullagh, Alan G. Porter